比奥纳斯抗癌药物筛选技术。

The Bionas technology for anticancer drug screening.

机构信息

University "Rey Juan Carlos" (URJC), Department of Health Sciences I, Laboratory of Histology and Cell Biology, Faculty of Health Sciences, Avda. de Atenas s/n, E-28922 Alcorcón, Madrid, Spain +34 91 4888640 ; +34 91 4888955 ;

出版信息

Expert Opin Drug Discov. 2009 Jul;4(7):785-97. doi: 10.1517/17460440903018840. Epub 2009 Jun 8.

DOI:10.1517/17460440903018840

PMID:23489169

Abstract

BACKGROUND

The Bionas 2500(®) analyzing system is an advanced label-free technology using a cell-based multi-sensor array, which is commercially available. Data on metabolism, respiration, adhesion, cell proliferation and cell death rates, as well as ligand-receptor interactions (multi-parametric) can be acquired and statistically evaluated. Noteworthy is the possibility of analyzing later after effects and/or recovery after drug treatment. In addition, Bionas supports all conceivable drug application modes (one, two or more drugs). Specimens for drug screening with Bionas consist of human permanent cell lines, primary cell cultures as well as 'tumor slices' obtained from biopsies and surgery material.

OBJECTIVE/METHODS: Examples of measurements are presented and discussed.

CONCLUSION

Although drug throughput is modest, the high quality of the information allows in-depth evaluation.

摘要

背景

Bionas 2500(®)分析系统是一种先进的无标记技术，使用基于细胞的多传感器阵列，可商业购买。可获得并统计评估代谢、呼吸、粘附、细胞增殖和细胞死亡率以及配体-受体相互作用（多参数）的数据。值得注意的是，在药物治疗后分析后续影响和/或恢复的可能性。此外，Bionas 支持所有可想象的药物应用模式（一种、两种或更多种药物）。Bionas 用于药物筛选的标本包括人永生化细胞系、原代细胞培养物以及从活检和手术材料获得的“肿瘤切片”。

目的/方法：介绍并讨论了测量示例。